ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2376

Behcet’s Disease: Combination of Pulse Cyclophosphamide, Azathioprine, and Prednisolone for the Treatment of Retinal Vasculitis; Longitudinal Study On 10 Years

Fereydoun Davatchi1, Farhad Shahram2, Bahar Sadeghi Abdollahi2, Hormoz Shams2, Abdolhadi Nadji2, Massoomeh Akhlaghi2, Tahereh Faezi2 and Farimah Ashofteh2, 1Rheumatology Research Ctr and Department of Rheumatology, Shariati Hospital-Tehran Univ, Tehran, Iran, 2Rheumatology, Behcet's Unit, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: azathioprine, Behcet's syndrome, ocular involvement and prednisolone, prednisone

  • Tweet
  • Email
  • Print
Session Information

Session Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Ocular lesions of Behcet’s Disease (BD), need aggressive treatment to prevent severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents and the first line treatment for it. Retinal vasculitis is the most aggressive lesion of ocular manifestations. It has the worse outcome. We present here the outcome with a combination of pulse cyclophosphamide, azathioprine, and prednisolone, on long-term usage up to 10 years on 291 patients (17286 eyes-months of follow-up).

Methods: Cyclophosphamide was used as one gram as monthly pulse for 6 months and then every 2 to 3 months as necessary. Azathioprine was used as 2 to 3 mg/kg/weight/daily. Prednisolone was associated as 0.5 mg/kg/ daily. Upon the suppression of the inflammatory reaction, prednisolone was tapered gradually. Inclusion Criteria: 1- Fulfilling the International criteria, the ICBD. 2- Having active posterior uveitis (PU) and/or retinal vasculitis (RV). Visual acuity (VA): was calculated by the Snellen chart on a scale of 10 (best vision 10/10). An activity index was calculated for PU and RV. A Total Adjusted Disease Activity Index (TADAI) was calculated for both eyes taking in account all parameters. Results were assessed at 3, 6, 9 months, then at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 10 years.  

Results: The mean improvement for Visual Acuity (p value) was: 0.9 (<0.001), 0.9 (<0.001), 0.9 (<0.001), 1.0 (<0.001), 0.8 (<0.001), 0.9 (<0.001), 0.9 (<0.001), 0.9 (<0.001), 1.1 (0.005), 0.1 (0.9), -0.5 (0.3), -0.5 (0.35), +2.0 (0.2), +2.9 (0.2), +0.3 (0.9). The mean improvement for Posterior Uveitis was: 1 (<0.001), 1.2 (<0.001), 1.5 (<0.001), 1.4 (<0.001), 1.4 (<0.001), 1.6 (<0.001), 1.6 (<0.001), 1.7 (<0.001), 1.9 (<0.001), 1.9 (<0.001), 1.9 (<0.001), 2 (<0.001), 2 (0.01), 2.8 (0.08), 1 (0.9). The mean improvement for Retinal Vasculitis was: 1.1 (<0.001), 1.7 (<0.001), 1.6 (<0.001), 1.6 (<0.001), 1.8 (<0.001), 1.7 (<0.001), 1.9 (<0.001), 1.8 (<0.001), 2.1 (<0.001), 2.2 (<0.001), 2.2 (<0.001), 1.8 (0.004), 6 (0.11), 4 (0), 2 (0). The mean improvement for TADAI was: 9.1 (<0.001), 11.7 (<0.001), 12.7 (<0.001), 11.9 (<0.001), 13 (<0.001), 13.8 (<0.001), 14.2 (<0.001), 14.6 (<0.001), 13.5 (<0.001), 16.3 (<0.001), 19.6 (<0.001), 17.1 (<0.001), 16.2 (0.6), 5.4 (0.2), 4 (0.6). Overall results (from baseline to the last evaluation): The mean VA improvement was 0.8 (<001), PU 1.4 (<0.001), RV 1.6 (<0.001), and TADAI 11 (<0.001). VA improved in 45.4% of eyes, PU in 75.6% of eyes, RV in 71.5% of eyes, and TADAI in 74.9% of patients. VA aggravated in 33% of eyes, PU in 14% of eyes, RV in 16.9% of eyes, and TADAI in 18.9% of patients. The remaining kept their baseline values. 

Conclusion: All parameters improved significantly. The improvement in VA was the least. It was mainly due to cataract. The non-significance of p values in the last years of follow-up was due to the low number of patients. Combination of pulse cyclophosphamide and azathioprine is the best treatment choice for retinal vasculitis before opting for biologic agents.


Disclosure:

F. Davatchi,
None;

F. Shahram,
None;

B. Sadeghi Abdollahi,
None;

H. Shams,
None;

A. Nadji,
None;

M. Akhlaghi,
None;

T. Faezi,
None;

F. Ashofteh,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/behcets-disease-combination-of-pulse-cyclophosphamide-azathioprine-and-prednisolone-for-the-treatment-of-retinal-vasculitis-longitudinal-study-on-10-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies